Document is current
Any future updates will be listed below
-
Authors
Molano-Franco, Daniel
Arevalo-Rodriguez, Ingrid http://orcid.org/0000-0002-7326-4504
Muriel, Alfonso
del Campo-Albendea, Laura
Fernández-García, Silvia
Alvarez-Méndez, Ana
Simancas-Racines, Daniel
Viteri, Andres
Sanchez, Guillermo
Fernandez-Felix, Borja
Lopez-Alcalde, Jesus
Solà, Ivan
Osorio, Dimelza
Khan, Khalid Saeed
Nuvials, Xavier
Ferrer, Ricard
Zamora, Javier
,
Estupiñan, Alvaro
Franco, Luis
Cardenas, Jorge
Robayo, Ivan
Villabon, Mario
Gomez, Mario
Stalling, Elena
Alvarez, Noelia
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI 19/0048)
- License Information
-
More Information
Article History
Received: 29 November 2022
Accepted: 13 July 2023
First Online: 3 August 2023
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Ferrer reports personal fees from Shionogi, personal fees from Pfizer, personal fees from MSD, personal fees from Gilead, personal fees from Menarini, personal fees from GSK during the conduct of the study. The remaining authors declare no competing interests.
